Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-09-06
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 299
- Registration Number
- NCT00372229
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5
- Registration Number
- NCT00368368
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 127
- Registration Number
- NCT00366379
A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-16
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 137
- Registration Number
- NCT00364832
A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-16
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT00365001
A Study of Mircera in Anemic Patients With Multiple Myeloma
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00360347
(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 170
- Registration Number
- NCT00354341
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2010-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 415
- Registration Number
- NCT00353418
A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 135
- Registration Number
- NCT00353522
A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT00353262
© Copyright 2024. All Rights Reserved by MedPath